关注声明：柯尼希，B.；基尔希纳，J.O. 关于新冠病毒mRNA疫苗Comirnaty中DNA杂质定量的方法学考量。2024年，，41。
Expression of Concern: König, B.; Kirchner, J.O. Methodological Considerations Regarding the Quantification of DNA Impurities in the COVID-19 mRNA Vaccine Comirnaty. 2024, , 41.
机构信息
MDPI, Grosspeteranlage 5, 4052 Basel, Switzerland.
出版信息
Methods Protoc. 2025 Jun 25;8(4):68. doi: 10.3390/mps8040068.
Abstract
Following publication [...].
摘要
在[……]发表之后。
相似文献
1
Expression of Concern: König, B.; Kirchner, J.O. Methodological Considerations Regarding the Quantification of DNA Impurities in the COVID-19 mRNA Vaccine Comirnaty. 2024, , 41.关注声明：柯尼希，B.；基尔希纳，J.O. 关于新冠病毒mRNA疫苗Comirnaty中DNA杂质定量的方法学考量。2024年，，41。
Methods Protoc. 2025 Jun 25;8(4):68. doi: 10.3390/mps8040068.
2
Methodological Considerations Regarding the Quantification of DNA Impurities in the COVID-19 mRNA Vaccine Comirnaty.关于新冠mRNA疫苗Comirnaty中DNA杂质定量的方法学考量
Methods Protoc. 2024 May 8;7(3):41. doi: 10.3390/mps7030041.
3
Comparative analysis of humoral immunity kinetics following three COVID-19 vaccines in a multi-ethnic cohort of medical students and healthcare professionals across Malaysia.马来西亚多民族医学生和医护人员队列中三种新冠疫苗接种后体液免疫动力学的比较分析
Sci Rep. 2025 Jul 1;15(1):21953. doi: 10.1038/s41598-025-07895-6.
5
A systematic review on mucocutaneous presentations after COVID-19 vaccination and expert recommendations about vaccination of important immune-mediated dermatologic disorders.一项关于 COVID-19 疫苗接种后黏膜皮肤表现的系统评价和关于重要免疫介导性皮肤病疫苗接种的专家建议。
Dermatol Ther. 2022 Jun;35(6):e15461. doi: 10.1111/dth.15461. Epub 2022 Apr 11.
6
Potency of BNT162b2 and mRNA-1273 vaccine-induced neutralizing antibodies against severe acute respiratory syndrome-CoV-2 variants of concern: A systematic review of in vitro studies.BNT162b2 和 mRNA-1273 疫苗诱导的针对严重急性呼吸综合征冠状病毒-2 变异株的中和抗体效力：体外研究的系统评价。
Rev Med Virol. 2022 Mar;32(2):e2277. doi: 10.1002/rmv.2277. Epub 2021 Jul 19.
7
Safety comparison of mRNA, viral vector, and inactivated Covid-19 vaccines: incidence of adverse events following primary and booster doses among medical professionals in Malaysia.mRNA、病毒载体和灭活新冠疫苗的安全性比较：马来西亚医疗专业人员中初次接种和加强剂量后不良事件的发生率
BMC Infect Dis. 2025 Jul 7;25(1):898. doi: 10.1186/s12879-025-11254-1.
8
Quantification of objective concentrations of DNA impurities in mRNA vaccines.mRNA疫苗中DNA杂质客观浓度的定量分析。
Vaccine. 2025 May 10;55:127022. doi: 10.1016/j.vaccine.2025.127022. Epub 2025 Mar 22.
9
Effective cellular and neutralizing immunity against SARS-CoV-2 after mRNA booster vaccination is associated with pDC and B cell activation.mRNA加强疫苗接种后对SARS-CoV-2产生有效的细胞免疫和中和免疫与浆细胞样树突状细胞（pDC）和B细胞活化有关。
Front Immunol. 2025 May 12;16:1580448. doi: 10.3389/fimmu.2025.1580448. eCollection 2025.
10
Vaccines for preventing infections in adults with haematological malignancies.用于预防血液系统恶性肿瘤成人感染的疫苗。
Cochrane Database Syst Rev. 2025 May 21;5(5):CD015530. doi: 10.1002/14651858.CD015530.pub2.
引用本文的文献
1
pDNA Impurities in mRNA Vaccines.mRNA疫苗中的质粒DNA杂质
Microorganisms. 2025 Aug 24;13(9):1975. doi: 10.3390/microorganisms13091975.
本文引用的文献
1
Quantification of objective concentrations of DNA impurities in mRNA vaccines.mRNA疫苗中DNA杂质客观浓度的定量分析。
Vaccine. 2025 May 10;55:127022. doi: 10.1016/j.vaccine.2025.127022. Epub 2025 Mar 22.
2
Methodological Considerations Regarding the Quantification of DNA Impurities in the COVID-19 mRNA Vaccine Comirnaty.关于新冠mRNA疫苗Comirnaty中DNA杂质定量的方法学考量
Methods Protoc. 2024 May 8;7(3):41. doi: 10.3390/mps7030041.
Zotero 插件